Modulation of doxorubicin concentration by cyclosporin A in brain and testicular barrier tissues expressing P-glycoprotein in rats

Journal of Neuro-Oncology

Volumn 37, Issue 1, 1998, Pages 45-54

  Hughes, Christine S ^a   Vaden, Shelly L ^a   Manaugh, Christine A ^a   Price, G Sylvester ^a   Hudson, L C ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

Blood tissue barrier; Cisplatin; Cyclosporin A; Doxorubicin; Multidrug resistance; P glycoprotein

Indexed keywords

ADENOSINE TRIPHOSPHATE; CISPLATIN; CYCLOSPORIN A; DOXORUBICIN; EVANS BLUE; FLUORESCEIN SODIUM; GLYCOPROTEIN P; HORSERADISH PEROXIDASE; MEMBRANE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD VESSEL PERMEABILITY; CANCER CHEMOTHERAPY; CAPILLARY ENDOTHELIUM; CELL PROTECTION; CELL TYPE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG TISSUE LEVEL; DRUG TRANSPORT; ENDOTHELIUM CELL; EPITHELIUM CELL; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY PROXIMAL TUBULE; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; TESTIS;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CISPLATIN; CYCLOSPORINE; DOXORUBICIN; EVANS BLUE; FLUORESCEIN; HORSERADISH PEROXIDASE; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; P-GLYCOPROTEIN; PLATINUM; RATS; RATS, INBRED F344; TESTIS; TISSUE DISTRIBUTION;

EID: 0031907402     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005900908540     Document Type: Article

References (31)

1. Holzmayer TA, Hilsenbeck S, Von Hoff DD, Roninson IB: Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Institute 84: 1486-1491, 1992
2. Ramachandran C, Sauerteig A, Sridhar KS, Thurer RJ, Krishan A: MDR-1 gene expression, anthacycline retention and cytotoxicity in human lung-tumor cells from refractory patients. Cancer Chemother Pharmacol 31:431-441, 1993
3. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84: 7735-7738, 1987
4. Fojo AT, Ueda K, Slamon DJ, Poplack DJ, Gottesman MM, Pastan I: Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84: 265-269, 1987
5. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Gruer L, Biedler JL, Melamed MR, Bertino JR : Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at the blood-brain barrier sites. Proc Nat Acad Sci USA 86: 695-698, 1989
6. Dermietzel RKD: Molecular anatomy of the blood-brain barrier as defined by immunocytochemistry. Intern Rev Cytol 127: 57-109, 1991
7. Dym M, Fawcett DW: The blood-testis barrier in the rat and the physiological compartmentation of the seminiferous epithelium. Biol Reprod 3: 308-326, 1970
8. Pardridge W: Peptide Drug Delivery to the Brain. Raven Press, New York, 1991
9. Tsuruo T, Iida H, Tsukagoshi S, Sakurai J: Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1967-1972, 1981
10. Tsuruo T, Iida H, Kititani Y, Yokada K, Tsukagoshi S, Sakurai Y: Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug resistant tumor cells. Cancer Res 44: 4303-4307, 1984
11. DeGregorio GW, Ford JM, Benz CC, Wiebe VJ: Toremifene: pharmacologic and pharmacokinetic basis of reversing multi-drug resistance. J Clin Oncol 7: 1359-1364, 1989
12. Ramu A, Glaubiger D, Fuks Z: Reversal of acquired resistance to doxorubicin in P388 murine cell leukemia cells by tamoxifen and other triparanol analogues. Cancer Res 44: 4392-4395, 1984
13. Siddik ZH, Newell DR, Boxall FE, Harrap KR: The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats. Biochem Pharmacol 36: 1925-1932, 1987
14. Yesair DW, Schwartzbach E, Shuck D, Denine EP, Asbell MA: Comparative pharmacokinetics of daunomycin and adriamycin in several animal species. Cancer Res 32: 1177-1183, 1972
15. Yeu-Tsu NL, Chan KK, harris PA: Tissue disposition of doxorubicin in experimental animals. Med Pediatric Oncol 10: 259-267, 1982
16. Hudson LC, Hughes CS, Fletcher-Bold N, Vaden SL: Cerebrospinal fluid collection in rats: modification of a previous technique. Lab Anim Sci 44: 358-361, 1994
17. Cox SK, Wilke AV, Frazier D : Determination of adriamycin in plasma and tissue biopsies. J Chromat Biomed Appl 564: 322-329, 1991
18. McGahan MC, Tyczkoska K: The determination of platinum in biological material by electrochemical atomic absorption spectroscopy. Spectrochimica Acta 42B: 665, 1987
19. Saria A, Lundberg JM: Evans blue fluorescence: quantitative and morphological evaluation of vascular permeability in animal tissues. J Neurosci Methods 8: 41-49, 1983
20. Wolman M, Klatzo I, Chui E, Wilmes F, Nishimoto K, Fujiwara K, Spatz M: Evaluation of the dye-protein tracers in pathophysiology of the blood-brain barrier. Acta Neuropathol 54: 55-61, 1981
21. Stewart PA, Farrell CR, Farrell CL, Hayakawa E: Horseradish peroxidase retention and washout in blood-brain barrier lesions. J Neurosci Methods 41: 75-84, 1992
22. Schinkel AH, Smit JJM, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, MolCAAM, van der Valk MA, Robanus-Maandag EC, te Riele HPJ, Berns AJM, Borst P: Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77: 491-502, 1994
23. Shirai A, Naito M, Tatsuta T, Dong J, Hanaoka K, Mikami K, Oh-hara T, Tsuruo T: Transport of cyclosporin A across the brain capillary endothelial cell monolayer by P-glycoprotein. Biochim Biophys Acta 1222: 400-404, 1994
24. Chan BBK, Kern JA, Flanagan, Terry L, Kron IL, Tribble CG: Effects of in vivo cyclosporine administration on endothelium-dependent responses in isolated vascular rings. Circulation 86: II-265-II-299, 1992
25. Nooter K, Oostrum R, Deurloo J: Effects of verapamil on the pharmacokinetics of daunomycin in the rat. Cancer Chemother Pharmacol 20: 176-178, 1988
26. Schrenk D, Gant T, Silverman J, Marino P, Thorgeirsson S: Induction of mdr expression by cholestasis: P-glycoprotein function as a biliary excretion pump. In: American Association for Cancer Research Annual Meeting, San Diego, 1992, 31
27. Trump DL, Smith DC, Ellis PG, Rogers MP, Schold SC, Winer EP, Panella TJ, Jordan VC, Fine RL: High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst 84: 1811-1816, 1992
28. Dudeja PK, Anderson KM, Harris JE, Coon JS: MDR reversal by surfactants: Relationship to membrane lipid physical state. In: Proceedings of the American Association for Cancer Research, San Francisco, Ca, 1994, 356
29. Moynihan TJ, Grossman SA: The role of chemotherapy in the treatment of primary tumors of the central nervous system. Cancer Invest 12: 88-97, 1994
30. Luthert PJ: Opening of the barrier in cerebral pathology. In: Bradburu MWB (ed) Physiology and Pharmacology of the Blood Brain Barrier. Springer-Verlag, New York, 1992, pp 440-441
31. Donelli MG, Zucchetti M, Incalci DX: Do anticancer agents reach the tumor target in the human brain? Cancer Chemother Pharmacol 30: 251-260, 1992